Loading…
COAG
Hemab Therapeutics Holdings, Inc.
NASDAQ· Healthcare· Biotechnology
$44.84-9.40%
Key metrics
- Market cap
- $2.09B
- P/E
- —
- Forward P/E
- —
- P/B
- 4.6x
- Dividend yield
- —
- EPS
- -$1.61
- ROE
- —
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $55.42
- 52-week low
- $23.00
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
- 59
- Cambridge, United States
Company description provided by Yahoo Finance.